To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

100 mg Aspirin Twice Daily Non-Inferior to Once Daily 10 mg Rivaroxaban for Prevention of VTE in THA

Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
February 2021

100 mg Aspirin Twice Daily Non-Inferior to Once Daily 10 mg Rivaroxaban for Prevention of VTE in THA

Vol: 10| Issue: 2| Number:36| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Comparable efficacy of 100 mg aspirin twice daily and rivaroxaban for venous thromboembolism prophylaxis following primary total hip arthroplasty: a randomized controlled trial

Chin Med J (Engl). 2021 Jan 5;134(2):164-172.

Contributing Authors:
Y Ren SL Cao Z Li T Luo B Feng XS Weng

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Seventy-eight patients undergoing a unilateral total hip arthroplasty (THA) were randomized in this non-inferiority trial to receive 5 weeks of aspirin (100 mg twice per day; n=37) or 5 weeks of rivaroxaban (10 mg once per day) post-operation for the prevention of deep vein thrombosis (DVT). The primary outcome of interest was the incidence of DVT which was assessed using Doppler ultrasonography a...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue